Surgery: light – thermal – and electrical application – Light – thermal – and electrical application – Light application
Reexamination Certificate
2000-10-02
2003-02-18
Walberg, Teresa (Department: 3742)
Surgery: light, thermal, and electrical application
Light, thermal, and electrical application
Light application
C607S092000, C606S015000, C606S007000, C606S003000, C604S020000
Reexamination Certificate
active
06520981
ABSTRACT:
FIELD OF THE INVENTION
This invention generally relates to the use of photodynamic therapy as a method to modulate the postintervention vascular injury healing response.
BACKGROUND OF THE INVENTION
Photodynamic therapy (PDT) is a technique in which wavelength-specific, visible light is applied to activate otherwise relatively nontoxic photosensitizer dyes (PS) to generate cytotoxic free-radicals. These PDT-generated free-radical moieties are thought to exert cytotoxic effects by lipid peroxidation of cellular membranes and organelles. Although initially developed for cancer therapy, there are a considerable number of recent experimental studies that examined PDT-mediated inhibition of intimal hyperplasia (IH) which is regarded as one important obstacle to a satisfactory long-term patency after invasive vascular procedures. Intimal hyperplasia originates from an injury to the blood vessel wall, resulting in luminal encroachment from cellular proliferation and matrix deposition. The biologic effects of PDT are strictly limited to the proximity of the PS molecules when they are light-activated, because the half-life of the free-radicals ranges in the area of microseconds. Since the necessary components for PDT-mediated effects include oxygen, PS, and light; the appropriate dosimetry, which is multifactorial, may be important for effective treatment.
The development of procedures to treat arterial occlusive disease represents an important area in the field of surgery. Besides vascular surgery, novel interventional techniques have been developed including balloon angioplasty, stent depolyment and atherectomy. However, restenosis remains the major obstacle to satisfactory long term patency after therapeutic interventions for the treatment of vascular disease. All forms of reconstruction, whether interventional or surgical, cause a degree of injury to the vessel wall, which result in a injury healing response. Intimal hyperplasia (IH) is defined as the early post-interventional migration of smooth muscle cells (SMC) and myofibroblasts into the subintimal space of the vessel, and leads to cell proliferation and the production of excessive amounts of matrix protein. Recent studies have shown that, in addition to IH through its production of a physical mass, changes can occur in arterial wall geometry. Defined as arterial remodeling, these changes can also play an important role by altering the artery circumference due to fibrotic contraction or compensatory dilatation. This process of arterial remodeling and the degree of IH together, determine whether and to what extent an artery will develop restenosis. Although the molecular basis of vascular postinterventional renarrowing is not fully understood, the development of restenotic lesions has been shown to involve the production of specific matrix molecules such as procollagen type I and the large chondroitin proteoglycan versican. These molecules modulate cell function (migration, proliferation), the activity of growth factors, and local concentrations of lipids in the vascular wall. Cell-matrix interactions may also provide the basis for constrictive remodeling, which resembles a similar phenomenon in a nonvascular injury response.
Among numerous mechanical and pharmacological approaches, several have been investigated to inhibit the occurrence of restenosis. However, only intravascular stents and ionizing irradiation have been proven to clinically reduce this process, however, they have not been without their own shortcomings such as restenosis and thrombosis and do not provide an adequate solution to the problem.
Therefore, a need exists for the treatment of IH and/or restenosis which addresses the limitations known within the art.
SUMMARY OF THE INVENTION
The present invention is directed to methods for modulating, e.g., preventing, inhibiting or minimizing, restenosis in a subject after the subject has had an intervention to reopen an obstructed blood vessel. This is performed by administering a therapeutically effective amount of a photosensitizer to the treated, injured site and irradiating this treated injured site with a therapeutically effective amount of light energy, such that restenosis in the subject is modulated. In preferred embodiments, the photosensitizer is benzoporphyrin-derivative monoacid ring at a concentration of 25 &mgr;g/ml and the energy is delivered by laser at about 690 nm with an energy value of about 100 J/cm
2
. In another preferred embodiment, the photosensitizer is methylene blue (MB) at a concentration of about 250 &mgr;g/ml to about 300 &mgr;g/ml and the energy is delivered by laser at about 660 nm with an energy value of about 100 J/cm
2
.
The present invention is also directed to methods for modulating, e.g., preventing, inhibiting or minimizing, intimal hyperplasia in a subject by administering a therapeutically effective amount of a photosensitizer to a therapeutically intervened site and irradiating the treated site with a therapeutically effective amount of light energy, such that intimal hyperplasia in the subject is modulated. Typically the subject is a mammal, e.g., a human, a mouse, a rat, a horse, a dog, or cat.
REFERENCES:
patent: 5019075 (1991-05-01), Spears et al.
patent: 5053033 (1991-10-01), Clarke
patent: 5354324 (1994-10-01), Gregory
patent: 5417653 (1995-05-01), Sahota et al.
patent: 5632767 (1997-05-01), Sinofsky
patent: 5776174 (1998-07-01), Van Tassel
patent: 5876426 (1999-03-01), Kume et al.
patent: 6107466 (2000-08-01), Hasan et al.
patent: WO 01/35996 (2001-05-01), None
patent: WO 01/35997 (2001-05-01), None
Adili et al. “Local delivery of photosensitizing drugs in arteries: A novel approach to photodynamic therapy for the prevention of intimal hyperplasia”SPIE2395: 402-408 (1995).
Coats et al. “Tin ethyl etipurpurin significantly inhibits vascular smooth muscle cell proliferation in vivo”,Biochem. Cell Biol.74: 325-331 (1996).
Heckenkamp et al. “Local photodynamic action of methylene blue favorably modulates the postinterventional vascular wound healing response”Journal of Vascular Surgery31 (61): 1168-1177 (2000).
Hsiang et al. “Dosage and timing of Photofrin to photodynamic therapy of intimal hyperplasia”Cardiovascular Surgery3 (5): 489-494 (1995).
Lambert et al. “Local drug delivery catheters: functional comparison of porous and microporous designs”Coronary Artery Disease4 (5): 469-475 (1993).
Orth et al. “Methylene blue mediated photodynamic therapy in experimental colorectal tumors in mice”Journal of Photochemistry and Photobiology B: Biology57: 186-192 (2000).
Vincent et al. “Effects of Benzoporphyrin Derivative Monoacid on Balloon Injured Arteries in a Swine Model of Restenosis”SPIE2671: 72-77 (1996).
Adili, F., et al., “Photodynamic Therapy with Local Photosensitizer Delivery Inhibits Experimental Intimal Hyperplasia,”Lasers in Surg. Med., vol. 23, 23; 263-273 (1998).
Adili, F., et al., “Significance of Dosimetry in Photodynamic Therapy of Injured Arteries: Classification of Biological Responses,”Photochem. Photobio., vol. 70, No. 4; 663-668 (1999).
Bryant, S.R., et al., “Vascular Remodeling in Response to Altered Blood Flow is Mediated by Fibroblast Growth Factor-2,”Cir. Res., vol. 84; 323-328 (1999).
Camenzkind, E., et al., “Use of Locally Delivered Conventional Drug Therapies,”Semin. Interv. Cardiol., vol. 1:67-76 (1996).
Clowes, A.W., “Pathologic Intimal Hyperplasia as a Response to Vascular Injury and Reconstruction,”Vascular Surgery, vol. 1; 285-295 (1995).
Coleman, M.D., et al., “Drug-Induced Methaemoglobinaemia,”Pharmacoepidemiology, vol. 14, No. 6; 394-405 (Jun. 1996).
Davies, M.G., et al., “Pathobiology of Intimal Hyperplasia,”British. J. of Surg., vol. 81; 1254-1269 (1994).
DeYoung, M.B., “Gene Therapy for Restenosis. Are We Ready?,”Circ. Res., vol. 82; 306-313 (1998).
Dubbleman, T., et al., “Photodynamic Therapy: Membrane and Enzyme Photobiology,”Photodynamic Therapy. Basic Principles and Clinical Applications, 37-46 (1992).
Eton, D., et al., “Photodynamic Therapy,”Arch Surg., vol. 130; 1098-1103 (1995).
Evanko, S.P., et al., “Formationof Hyaluro
Dahbour Fadi H.
Nutter & McClennen & Fish LLP
The General Hospital Corporation
Walberg Teresa
LandOfFree
Significance of dosimetry in photodynamic therapy of injured... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Significance of dosimetry in photodynamic therapy of injured..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Significance of dosimetry in photodynamic therapy of injured... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3169441